Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding

Am J Hematol. 2016 Jun;91(6):E313-4. doi: 10.1002/ajh.24367. Epub 2016 Apr 28.

Authors

Narendranath Epperla¹, Jonathan T Kapke², Matthew Karafin³, Kenneth D Friedman¹, Patrick Foy¹

Affiliations

¹ Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
² Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
³ Division of Transfusion Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

PMID: 26994402
DOI: 10.1002/ajh.24367

No abstract available

Publication types

Letter

MeSH terms

Adult
Antineoplastic Agents, Immunological / administration & dosage*
Bevacizumab / administration & dosage*
Female
Hemorrhage / etiology
Hemorrhage / prevention & control*
Humans
Male
Middle Aged
Telangiectasia, Hereditary Hemorrhagic / drug therapy*
Telangiectasia, Hereditary Hemorrhagic / physiopathology

Substances

Antineoplastic Agents, Immunological
Bevacizumab